Patients with unique activating genetic variants in the EGFR tyrosine kinases region profit more from FDA-approved drugs (exons 18–21). The most frequent EGFR-activating alterations are exon 19 deletions (del19) (45 percent) and the L858R exon 21 replacement (40–45 percent). Exon 18 alteration make up just approximately 5 percent of all EGFR mutations, which is a significantly lower frequency [14, 15]. Figure 1 mentioned recently approved EGFR-TKI drugs as its targeted therapy for lung cancer.

Exon 19 deletion mutations, advanced disease stages, prolonged treatment, and the usage of third-generation EGFR-TKIs were all linked to greater disease-free survival (DFS) benefits. Combining therapy EGFR-TKIs should enhance DFS but not Overall Survival (OS) in EGFR mutation-positive patients with stage IB-IIIA NSCLC therapy EGFR-TKIs should enhance DFS but not OS in EGFR mutation-positive patients with stage IB-IIIA NSCLC when compared to subsequent chemotherapy or placebo. The illness stage, length of the treatment, types of mutation, and therapeutic drugs may all have an impact on the degree of effect. Adjuvant EGFR-TKIs demonstrated better tolerance than chemotherapy, especially when first-generation medicines were used [17]. Various clinical trials are undergoing like Wu 2020 (ADURA) [18], Zhong 2018 (ADJUVANT) [19], Yue 2018 (EVAN) [20], Li 2014 [21], Kelly 2015 (RADIANT) [22]. Numerous recent trials have looked into the efficacy of EGFR-TKI therapy as a preoperative treatment for NSCLC. Preoperative EGFR-TKI therapy has the capability to decrease tumor size, enhance radiological outcomes, and boost the likelihood of curative surgery. The effectiveness and safety of neoadjuvant EGFR-TKI treatment were assessed using a pooled analysis of prospectively trial information. Patients having treatable EGFR-variant NSCLC can get adjuvant chemotherapy, EGFR-TKI, or a combination of the two, albeit which is the most beneficial remains unknown. It should be looked into given the superior objective response rate, surgical resection rate, and safety of neoadjuvant EGFR-TKI over chemotherapy for potentially resectable NSCLC. Patients with operable EGFR-mutant NSCLC have access to subsequent chemotherapy, EGFR-TKI, or a combination of the two, while it is debatable which is the most effective. Given the improved objective response rate, surgical resection rate, and safety of preoperative EGFR-TKI over chemotherapy for potentially resectable NSCLC, it should be investigated [23]. Table 1 mentioned recently approved EGFR- TKI and their clinical status.

In 2022, a novel family of EGFR-TKIs will be developed through structural changes of 2,4-dihydroindeno[1,2-c]pyrazoles. These chemicals were compared to erlotinib’s potency [27] (The sponsor decided to discontinue the trial after deciding to examine the pairing of quaratusugene ozeplasmid and osimertinib rather than quaratusugene ozeplasmid and erlotinib [28]). The US FDA granted fast-track designation to a pair of quaratusugene ozeplasmid immunogene therapy and pembrolizumab for the treatment of patients with relapsed stage III or IV NSCLC who had already worsened on pembrolizumab [29]. Currently, phase II and III trials are being conducted to compare osimertinib against osimertinib plus chemo treatment, such as cisplatin/carboplatin and pemetrexed. The OPAL Study (NEJ032C/LOGIK1801) is a phase II study of osimertinib in association with platinum with pemetrexed in patients suffering from advanced NSCLC who have EGFR mutations [30]. Combination chemotherapy can also boost the number of people in remission. The patient with EGFR-mutated advanced NSCLC underwent well-tolerated combination therapy and benefited from osimertinib in conjunction with chemotherapy and bevacizumab [31]. For first-line chemotherapy, a combination of osimertinib and gefitinib is acceptable [32] as well as second-line treatment (OSCILLATE) [33] of EGFR-modified NSCLC resulted in fast plasma clearance of the EGFR mutation. Dual EGFR inhibition with gefitinib + osimertinib may postpone the establishment of acquired resistance, according to preclinical research [32].

Just for knowledge, osimertinib was compared to afatinib for the treating of 790M-positive NSCLC and numerous central nervous system (CNS) lesions after lack of first EGFR-TKI medication in an Asian population, and osimertinib was found to be superior to afatinib [34].

Regardless of the fact that chemotreatment and radiotherapy are treatment options for lung malignancy, the majority of patients experience a recurrence that is more resistant to subsequent treatment. A promising pharmacological approach is required to improve the prognosis of this type of cancer. Significant improvements in the research and the utilization of nanotechnology in the diagnostic and treatment of this form of cancer have been made in recent years, including the usage of LBNPs [35]. Nanomedicine is a comparatively recent treatment that aims to replace drug delivery and boost therapeutic advantages while limiting negative impacts on healthy tissues [36]. Blood circulation and clearance of the drug provide balance between its activity and toxicity. Due to the physicochemical properties of the nanomaterials, it mainly distributed in lung, liver, and kidney hence their clearance is expected to occur from these organs. The safety and effectiveness of nanocarriers are not assured and cannot be precisely managed due to the unknown processes of absorption, distribution, metabolism, and excretion, also the drug release mechanism of nanocarriers in the body. Therefore, they are rarely approved for clinical usage [37, 38]. On consideration of toxicity human body there is 2 types of toxicity e.g., primary [inflammation, oxidative stress, deoxyribonucleic acid (DNA) damage by direct exposure to organs like lung, skin, etc.] and secondary (inflammation, ROS generation, altered cellular function, etc.) [39]. Therefore, very least are actually there in clinical trials recently for lung cancer as mentioned in Table 2.

Despite the success of different drug delivery systems in recent years, there are yet certain challenges that be resolved and advanced technologies to be developed in order to successfully carry pharmaceuticals to their local sites. As a result, nano-based drug delivery devices are still researched to aid in improved drug delivery [40]. Two types of NPs used in the treatment of lung cancer, organic NPs (liposomes, solid lipid nanoparticle, nanostructued liquid carriers, polymeric NP, colloidal polymeric micelles, dendrimer, etc.) and inorganic NPs (quantum dots, magnetic NPs, carbon nanotubes, etc.) [41]. Figure 2 mentioned the various nanomaterials depending on their physicochemical properties.

There are numerous advantages of using NPs over other materials. Because of the enhanced permeability and retention (EPR) action, NPS can stay in the tumour location. Another virtue of NPS is that its surface may be easily modified to reduce inappropriate ingestion by the reticuloendothelial system [42]. The large surface-area-to-volume ratio is another feature that permits therapeutic compounds to be held successfully and not degraded by the microenvironment. Nanomaterials are also being used to produce more effective and regulated drug delivery techniques [40]. Nanotechniques have proven to bridge the gap among biological and morphological sciences through the use of nanostructures and nanophases in a wide range of scientific domains [43]. Such particles are very important in nanomaterials and medication delivery systems based on nanotechnology [44, 45].

Nanostructures stay in the bloodstream for a long period of time, allowing coupled drugs to be delivered at the appropriate dose. As a result, they cause less plasma fluctuations and have fewer negative impacts. These nanostructures penetrate the tissue matrix, allowing for easy drug uptake by cells, efficient drug distribution, and targeted action. Nanostructures are substantially easier for cells to consume than large particles with sizes ranging from 1 to 10 µm [46, 47]. NPs provide the best way to deliver natural compounds with high safety and efficacy. These nanomaterials are labeled with drugs that have minimal penetration and ingestion [47, 48]. Thus, nanotechnology provides relevant qualifications in the treatment of lung cancer via location specific and goal-oriented medication delivery [40]. NP based medicines developed not just for treatment but also for diagnosis, imaging, detection, etc. of the lung cancer [49].

Getting the drug to the proper place in the body while limiting any unwanted effects on healthy organs is one of the most complex aspects of drug transmission. This is especially challenging in cure for cancer because the tumor may appear as an organ lesion. These strategies are aided by certain NPs. These benefits include their tiny size, which enables them to pass through cell membranes, link and stabilize peptides, and exit from lysosomes following endocytic [50]. The goal of drug capture in nanotechnology is to either boost release of the drug to or ingestion by specific receptors, or to reduce the toxic effects of the free drug to non-target systems. Lengthy and target-specific nanomaterials are required to achieve these goals. NP capture in the liver and spleen’s cellular eosinophils system is one of the issues [51]. Irrespective of how the treatment is administered, the bloodstream’s bioavailability permits active substance to travel to and contact practically all tissues throughout the body, and once there is drug content in the circulation, it can pass through endothelium obstacles. To build exact localization, a transporter that can disperse the medicine directly towards the target area can be used [52]. After NPs reach the intended region via systemic circulation, the interaction of ligands and receptors is referred to as active targeting. Only close proximity (0.5 nm) between the two components allows for ligand-receptor interaction [53]. Polyethylene glycol (PEG) surface renovation culminated in longer bloodstream circulation by blocking identification and consumption by the single-nuclear engulfing system [54]. Surface charge and other chemical characteristics may influence NP fate in cells. Gold NPs with PEG surfaces were effectively up taken in endosomes and cytoplasm, with nuclear localization [55]. Cells ingested poly(DL-lactide-co-glycolide) NPs by endocytosis [56, 57]. carbohydrate-binding agents to increase cellular contact on the interface of both biocompatible and biodegradable polylactic-co-glycolic acid (PLGA) nanospheres [58]. When the drug is administered as NPs or incorporated into them, higher adherence may contribute to improved drug activity. The attachment of certain peptides, like antibodies, to the nanomaterial surface may allow for more precise immunologically directed particle localization [59, 60]. Antibodies (immunoglobulin) are a crucial component in the formation of a system that actively targets NPs. Single-chain segment factors and antibody antigen-binding segments have two lighter and heavier chains that can bind sensors or antigen, respectively [61]. Folate, often known as folic acid belongs to the B vitamin family. It is a glycosylphosphatidylinositol-anchored cell-surface receptor, and this system is a ligand that is ideal for targeting tumor cells [62]. Aptamers are non-toxic targeting ligands that have more flexibility, stability, low molecular weight, and repeatability, than natural antibodies [52]. Table 3 mentioned the recent NP formulations of EGFR TK anticancer drugs.

Table 4 mentioned newer combinations of anticancer NP formulations respectively.

SLNs are a novel dispersed drug administration technique constituted of biological oily material which remained solid at ambient and internal temperatures [35]. SLN has the potential to transport both hydrophilic and lipophilic medicines, as well as a high level of stability, extended bloodstream persistence, and the ability to be created from biocompatible materials [83]. These particles range in size from 50 to 1,000 nm. Solid lipids used as a solid material for drug encoring possessing monosaccharides, fatty acids, disaccharides, triglycerides, and compound glyceride mixtures. This matrix is stabilized by a mixture of surfactants or polymers [35]. SLNs pair the characteristics of a fat-emulsion carrier, liposome carrier, and polymeric NP, building them ideal for localized drug administration [84]. The ability of SLN to transfer the commonly used cytostatic (5-fluorouracil) through A549 cells’ resistance [85]. Treatment of NSCLC with microparticles containing erlotinib-loaded SLN by formulating dry powder inhaler to increase cargo drug molecule in alveoli adenocarcinoma over oral dosage of erlotinib [86]. Cetyl alcohol, Compritol 888 ATO, bee wax, cholesterol butyrate, and emulsifying wax are the most often utilized solid lipids for making SLN [87]. As per Wioletta Zielińska [88] possibilities for using SLNs in combination with 5-fluorouracil to defeat NSCLC cell line A549’s drug resistance. Unfortunately, like other colloidal systems, the SLNs have low drug loading, which is restricted by the drug’s solubility in the melting lipid phase and its ejection during storage [89, 90]. Afatinib-loaded SLN and paclitaxel delivered via PLGA porous microspheres dry powders: a newer therapy for EGFR inhibitors of tyrosine kinase NSCLC resistant. Author showed that combination of the EGFR-TKI with other chemotherapeutic agent would be feasible to overcome resistant over resistance produced by sing EGFR-TKI [91].

NLC (nanostructured lipid carriers) are second-generation lipid-based NPs that were first published in the mid-1990s to address the drawbacks of SLNs [92]. NLC are formed up of solid and liquid lipids that have been partially crystallized and dispersed in an aqueous phase containing an emulsifier [91]. This loosely packed crystalline structure allows drug molecules to be entrapped, reducing drug leakage during storage and allowing regulated drug release [93]. The NLC system has a low drug loading capacity because of the crystalline structure of the lipids and gelation in the dispersed phase due to solid lipid polymorphism [94]. In 2019, researchers compared erlotinib-loaded NLC and liposomes vs. the A549 lung cancer cell line in vitro. Erlotinib-NLC were more effective against cancer than erlotinib-liposomes mentioned in Table 4 [67].

Polymeric NPs have already been widely studied in the treatment for cancer [95]. Polymers with a variety of structures, both natural and manufactured, can be used. Since they are biocompatible and biodegradable, polypeptides, albumin, gelatin, and chitosan are among the most often utilized natural polymers. Among the synthetic polymers utilized are PEG, polylactic acid, PLGA, and polycaprolactone [96]. Their use of polymeric NP allows maximum packaging of hydrophobic medicines, resulting in longer circulation durations and more effective enforcement at the site of action, as well as an improvement in therapeutic and targeting agent efficacy [97]. The goal of Vaidya’s study [98] was to create a NP method to overcome erlotinib resistance in patients of NSCLC. Erlotinib-cyclodextrin complex was synthesized using cyclodextrin sulfobutyl ether, which was then loaded into the core of biodegradable PLGA NPs via repeated emulsion solvent evaporation. Cationic polymers are known for their cellular toxicity and enhanced clumping in lung capillaries because they are non-degradable and poor compliance. As a result, constant monitoring of cationic polymer-induced toxicity is essential, as they cause dyspnea when they combine with a biosurfactant [99].

Micelles are amphiphilic block copolymer nanomaterials that self-collected in a watery solution that build a conceptual model [40]. Polymeric micelles have a restricted dispersion to avoid too fast elimination through kidney, allowing them to concentrate in carcinomal parts via the EPR effect. Their polymeric coating also minimizes unwanted interactions with bioactive molecules. Their inner space structure allows for drug assimilation, which enhances stability and bioavailability, these nanomaterials have a lot of potential for water hating material transportation [100, 101]. The biodegradable nature of this technique for drug delivery systems, which may be employed for both cancer and eye medication administration, is its main advantage [41]. There are many formulations of EGFR-TKI which were signified for HER2 overexpression, synergistic effect, and multidrug resistance [102].

Regardless of how the medication is delivered, the bioavailability of the blood permits drug particles to diffuse and get into practically all tissues in the body that are affected, and once the medication is in circulation, it crosses capillary boundaries. A carrier that redistributes the medicine selectively toward the target tissue can be employed to accomplish correct targeting [103]. Drug solubility and drug targeting (active and/or passive targeting) are both affected by dendrimers. Dendrimers have been used to diagnose diseases, particularly malignancies; consequently, we will focus on their diagnostic uses and briefly explore their capacity to deliver anticancer medications here [104]. Dendrimers offer a wide range of applications owing to their functional and structural diversity. They can be used in a variety of applications, possessing gene and small interfering ribonucleic acid (siRNA) delivery, pharmacy, photodynamic therapy, biomedicine, oligonucleotide conjugation, immunology, and imaging [105].